Goldman Sachs
SMMT icon

Goldman Sachs’s Summit Therapeutics SMMT Stock Holding History

Goldman Sachs’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,100
Closed -$832K – 6630
2025
Q2 		$832K Hold
39,100
– – ﹤0.01% 4827
2025
Q1 		$754K Buy
+39,100
New +$784K ﹤0.01% 4912
2024
Q4 		– Sell
-36,400
Closed -$797K – 6246
2024
Q3 		$797K Buy
+36,400
New +$509K ﹤0.01% 4791

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs's SMMT Position: Q1 2026 in Review

Goldman Sachs reduced its Summit Therapeutics (SMMT) stake by 36% in Q1 2026, selling an estimated $2.83M and leaving 310,728 shares worth $5.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3538.

Goldman Sachs first reported a position in SMMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.2M in Q4 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Goldman Sachs held 310,728 shares of Summit Therapeutics worth $5.89M as of Q1 2026.
  • Goldman Sachs sold 174,838 Summit Therapeutics shares in Q1 2026, an estimated $2.83M.
  • Summit Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3538 holding.
  • Goldman Sachs first reported a position in Summit Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Summit Therapeutics position peaked at $16.2M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.